文献速递贫血与红细胞疾病

用地拉罗司治疗的β-地中海贫血重型的患者心脏磁共振长期改善延伸至基线心功能异常的患者

Long-term improvement in cardiac magnetic resonance in β-thalassemia major patients treated with deferasirox extends to patients with abnormal baseline cardiac function.
PubMed 文献 · Am J Hematol · 2018-12-11

本研究在98例接受地拉罗司(DFX)平均6.9年(范围1.8-11.6年)的真实世界β-地中海贫血重型患者中,评估心脏磁共振T2*、心功能参数及心血管临床事件。全人群心脏T2*显著增加(+2.6 ± 11.9毫秒;P=0.035),心脏铁过载(T2*<20毫秒)患者增加更显著(+11.6 ± 15.5毫秒,P=0.019)。基线心功能异常者中首次观察到DFX诱导的LVEF改善(从50.6 ± 6升至60.2 ± 5;P=0.001),无心脏死亡或新发心力衰竭。

要点

  • 98例β-地中海贫血重型患者接受DFX平均6.9年,无心脏死亡或新发心力衰竭。
  • 全人群心脏T2*显著增加+2.6 ± 11.9毫秒(P=0.035),心脏铁过载者增加更显著。
  • 基线心功能异常者中首次观察到DFX诱导的LVEF改善,作者认为需进一步评估。

核心结论

  • DFX可有效维持心脏铁水平在正常范围并改善心脏铁过载,长期观察至12年未见心力衰竭或心脏死亡。
  • 首次在基线心功能异常的患者亚组中观察到DFX诱导的LVEF改善,作者认为这一初步观察值得进一步评估。

研究设计与样本

  • 研究为真实世界环境下的纵向队列研究,纳入98例接受DFX治疗的β-地中海贫血重型患者,平均暴露6.9年(范围1.8-11.6年)。
  • 评估指标为心脏磁共振T2*、心功能参数及心血管临床事件的纵向变化。

主要发现

  • 全人群心脏T2*显著增加(+2.6 ± 11.9毫秒;P=0.035)。
  • 心脏铁过载(T2*<20毫秒)患者心脏T2*增加更显著(+11.6 ± 15.5毫秒,P=0.019)。
  • 13例心功能恢复正常(LVEF>56%)的患者中,11例(84.6%)LVEF显著改善(从50.6 ± 6升至60.2 ± 5;P=0.001)。
  • 心律失常是最常见的心脏不良事件,但无一导致DFX停药。

临床怎么用

  • 作者认为DFX可有效维持心脏铁水平在正常范围并改善心脏铁过载。
  • 作者认为基线心功能异常患者中DFX诱导的LVEF改善为初步观察,值得进一步评估。

局限性

  • 作者认为基线心功能异常患者中DFX诱导的LVEF改善为初步观察,值得进一步评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The management of iron overload in thalassemia has changed dramatically since the implementation of magnetic resonance imaging, which allows detection of preclinical iron overload and prevention of clinical complications. This study evaluated the effect of deferasirox (DFX), the newest once-daily oral chelator, on cardiac function, iron overload and cardiovascular events over a longer follow up in a "real world" setting. Longitudinal changes in cardiac magnetic resonance T2*, cardiac function parameters and cardiovascular clinical events were assessed in a cohort of 98 TM patients exposed to DFX for a mean of 6.9 years (range 1.8-11.6 years). No cardiac death or incident heart failure occurred. Cardiac T2* significantly increased (+2.6 ± 11.9 msec; P = 0.035) in the whole population, with a significantly greater increase (+11.6 ± 15.5 msec, P = 0.019) in patients with cardiac iron overload (T2* <20 ms). A significant improvement in left-ventricular ejection fraction (LVEF) (from 50.6 ± 6 to 60.2 ± 5; P = 0.001) was observed in 11 (84.6%) out of 13 patients who normalized cardiac function (LVEF >56%). Arrhythmias were the most frequent cardiac adverse event noted but none led to DFX discontinuation. Our data indicate that DFX is effective in maintaining cardiac iron level in the normal range and in improving cardiac iron overload. No heart failure or cardiac death was reported over this longer observation up to 12 years. For the first time, a DFX-induced improvement in LVEF was observed in a subgroup of patients with abnormal cardiac function at baseline, a preliminary observation which deserves further evaluation.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Casale M, Filosa A, Ragozzino A, et al. Long-term improvement in cardiac magnetic resonance in β-thalassemia major patients treated with deferasirox extends to patients with abnormal baseline cardiac function. Am J Hematol. 2018. PMID: 30489651. doi:10.1002/ajh.25370

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。